Browse > Article
http://dx.doi.org/10.3904/kjim.2018.159

Vibrio vulnificus infection: a persistent threat to public health  

Yun, Na Ra (Division of Infectious Disease, Department of Internal Medicine, Chosun University College of Medicine)
Kim, Dong-Min (Division of Infectious Disease, Department of Internal Medicine, Chosun University College of Medicine)
Publication Information
The Korean journal of internal medicine / v.33, no.6, 2018 , pp. 1070-1078 More about this Journal
Abstract
Vibrio vulnificus is a gram-negative bacterium that can cause serious, potentially fatal infections. V. vulnificus causes three distinct syndromes: an overwhelming primary septicemia caused by consuming contaminated seafood, wound infections acquired when an open wound is exposed to contaminated warm seawater, and gastrointestinal tract-limited infections. Case-fatality rates are higher than 50% for primary septicemia, and death typically occurs within 72 hours of hospitalization. Risk factors for V. vulnificus infection include chronic liver disease, alcoholism, and hematological disorders. When V. vulnificus infection is suspected, appropriate antibiotic treatment and surgical interventions should be performed immediately. Third-generation cephalosporin with doxycycline, or quinolone with or without third-generation cephalosporin, may be potential treatment options for patients with V. vulnificus infection.
Keywords
Vibrio vulnificus; Diagnosis; Therapeutics; Prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Yu W, Shen X, Pan H, Xiao T, Shen P, Xiao Y. Clinical features and treatment of patients with Vibrio vulnificus infection. Int J Infect Dis 2017;59:1-6.   DOI
2 Lin YS, Hung MH, Chen CC, Huang KF, Ko WC, Tang HJ. Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: case report in a child. J Microbiol Immunol Infect 2016;49:138-141.   DOI
3 Kuo Chou TN, Chao WN, Yang C, Wong RH, Ueng KC, Chen SC. Predictors of mortality in skin and soft-tissue infections caused by Vibrio vulnificus. World J Surg 2010;34:1669-1675.   DOI
4 Chen SC, Chan KS, Chao WN, et al. Clinical outcomes and prognostic factors for patients with Vibrio vulnificus infections requiring intensive care: a 10-yr retrospective study. Crit Care Med 2010;38:1984-1990.   DOI
5 Kim DM, Jung SI, Jang HC, et al. Vibrio vulnificus DNA load and mortality. J Clin Microbiol 2011;49:413-415.   DOI
6 Lee JY, Kim DM, Yun NR, et al. Tumor necrosis factor-$\alpha$ and mortality in patients infected with Vibrio vulnificus. Am J Trop Med Hyg 2011;84:426-428.   DOI
7 Centers for Disease Control and Prevention. Summary of human Vibrio isolates reported to CDC, 2004 [Internet]. Atlanta (GA): CDC, 2004 [cited 2018 May 21]. Available from: https://www.cdc.gov/nationalsurveillance/pdfs/vibrio2004.pdf.
8 Bross MH, Soch K, Morales R, Mitchell RB. Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician 2007;76:539-544.
9 Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food: 10 States, United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:392-395.
10 Hsueh PR, Lin CY, Tang HJ, et al. Vibrio vulnificus in Taiwan. Emerg Infect Dis 2004;10:1363-1368.   DOI
11 Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination: a review of Vibrio vulnificus septicemia. Am J Gastroenterol 2005;100:1195-1199.   DOI
12 Daniels NA. Vibrio vulnificus oysters: pearls and perils. Clin Infect Dis 2011;52:788-792.   DOI
13 Johnston JM, Becker SF, McFarland LM. Vibrio vulnificus. Man and the sea. JAMA 1985;253:2850-2853.   DOI
14 Barton JC, Acton RT. Hemochromatosis and Vibrio vulnificus wound infections. J Clin Gastroenterol 2009;43:890-893.   DOI
15 Park SD, Lee JY, Kim HD, Yoon NH. Clinical study of Vibrio vulnificus sepsis. Korean J Dermatol 2006;44:696-707.
16 Wright AC, Simpson LM, Oliver JD. Role of iron in the pathogenesis of Vibrio vulnificus infections. Infect Immun 1981;34:503-507.
17 Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother 2002;46:1741-1745.   DOI
18 Neupane GP, Kim DM. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion 2009;49:1762-1769.   DOI
19 Lee SH, Chung BH, Lee WC. Retrospective analysis of epidemiological aspects of Vibrio vulnificus infections in Korea in 2001-2010. Jpn J Infect Dis 2013;66:331-333.   DOI
20 Shin YH, Lee JK, Oh KS, et al. National surveillance of Vibrio vulnificus infections in 1998. Korean J Infect Dis 1999;31:232-236.
21 Kim DM, Hong SJ. Vibrio vulnificus sepsis. Korean J Med 2012;82:671-679.   DOI
22 Kim CS, Bae EH, Ma SK, Kim SW. Severe septicemia, necrotizing fasciitis, and peritonitis due to Vibrio vulnificus in a patient undergoing continuous ambulatory peritoneal dialysis: a case report. BMC Infect Dis 2015;15:422.   DOI
23 Chuang YC, Yuan CY, Liu CY, Lan CK, Huang AH. Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis 1992;15:271-276.   DOI
24 Yun NR, Kim DM, Lee J, Han MA. pH level as a marker for predicting death among patients with Vibrio vulnificus infection, South Korea, 2000-2011. Emerg Infect Dis 2015;21:259-264.   DOI
25 Ok HS, Kim BK, Kim KH, et al. Vertebral osteomyelitis resulting from hematogenous spread of Vibrio vulnificus gastroenteritis. Korean J Med 2014;86:519-522.   DOI
26 Shapiro RL, Altekruse S, Hutwagner L, et al. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis 1998;178:752-759.   DOI
27 Klontz KC, Lieb S, Schreiber M, Janowski HT, Baldy LM, Gunn RA. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988;109:318-323.   DOI
28 Chen Y, Satoh T, Tokunaga O. Vibrio vulnificus infection in patients with liver disease: report of five autopsy cases. Virchows Arch 2002;441:88-92.   DOI
29 Merkel SM, Alexander S, Zufall E, Oliver JD, Huet-Hudson YM. Essential role for estrogen in protection against Vibrio vulnificus-induced endotoxic shock. Infect Immun 2001;69:6119-6122.   DOI
30 Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis 2008;46:970-976.   DOI
31 Tacket CO, Brenner F, Blake PA. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis 1984;149:558-561.   DOI
32 Ma KA, Lee SM, Kim MS, et al. Emergency debridement with empirical antibiotics treatment for clinically diagnosed Vibrio sepsis. Korean J Infect Dis 1997;29:297-303.
33 Lee JY, Kim SW, Kim DM, Yun NR, Kim CM, Lee SH. Clinical usefulness of real-time polymerase chain reaction for the diagnosis of Vibrio vulnificus infection using skin and soft tissues. Am J Trop Med Hyg 2017;97:443-446.   DOI
34 Kim HS, Kim DM, Neupane GP, et al. Comparison of conventional, nested, and real-time PCR assays for rapid and accurate detection of Vibrio vulnificus. J Clin Microbiol 2008;46:2992-2998.   DOI
35 Ryu HH, Lee JY, Yun NR, Kim DM. Necrotizing soft tissue infection with gas formation caused by Vibrio vulnificus and misdiagnosed as Pseudomonas aeruginosa. Am J Emerg Med 2013;31:464.
36 Halow KD, Harner RC, Fontenelle LJ. Primary skin infections secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg 1996;183:329-334.
37 Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998;64:397-400.
38 McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-563.   DOI
39 Han F, Walker RD, Janes ME, Prinyawiwatkul W, Ge B. Antimicrobial susceptibilities of Vibrio parahaemolyticus and Vibrio vulnificus isolates from Louisiana Gulf and retail raw oysters. Appl Environ Microbiol 2007;73:7096-7098.   DOI
40 Chao WN, Tsai CF, Chang HR, et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis. Am J Surg 2013;206:32-39.   DOI
41 Bowdre JH, Hull JH, Cocchetto DM. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther 1983;225:595-598.
42 Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 1997;41:2214-2217.   DOI
43 Tang HJ, Chang MC, Ko WC, Huang KY, Lee CL, Chuang YC. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 2002;46:3580-3584.   DOI
44 Kim DM, Lym Y, Jang SJ, et al. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob Agents Chemother 2005;49:3489-3491.   DOI
45 Jang HC, Choi SM, Kim HK, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One 2014;9:e101118.   DOI
46 Centers for Disease Control and Prevention. Vibrio vulnificus: general information [Internet]. Atlanta (GA): CDC, 2018 [cited 2018 May 21]. Available from: https://www.cdc.gov.
47 Chen SC, Lee YT, Tsai SJ, et al. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period. J Antimicrob Chemother 2012;67:488-493.   DOI
48 Trinh SA, Gavin HE, Satchell KJF. Efficacy of ceftriaxone, cefepime, doxycycline, ciprofloxacin, and combination therapy for Vibrio vulnificus foodborne septicemia. Antimicrob Agents Chemother 2017;61:e01106-17.